Sarah Grimwood
Pfizer (United States)(US)
Publications by Year
Research Areas
Neuroscience and Neuropharmacology Research, Receptor Mechanisms and Signaling, Neurotransmitter Receptor Influence on Behavior, Pharmacological Receptor Mechanisms and Effects, Ion channel regulation and function
Most-Cited Works
- → Design and Selection Parameters to Accelerate the Discovery of Novel Central Nervous System Positron Emission Tomography (PET) Ligands and Their Application in the Development of a Novel Phosphodiesterase 2A PET Ligand(2013)199 cited
- → 4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDA receptor(1992)187 cited
- → Target site occupancy: Emerging generalizations from clinical and preclinical studies(2009)130 cited
- → Effect of Plasma Protein Binding on in Vivo Activity and Brain Penetration of Glycine/NMDA Receptor Antagonists(1997)129 cited
- → Identification of Molecular Determinants That Are Important in the Assembly of N-Methyl-d-aspartate Receptors(2001)114 cited
- → Duration of Action of a Broad Range of Selective κ-Opioid Receptor Antagonists Is Positively Correlated with c-Jun N-Terminal Kinase-1 Activation(2011)104 cited
- → NR2B-containing NMDA receptors are up-regulated in temporal cortex in schizophrenia(1999)89 cited
- → Anticonvulsant activity of glycine-site NMDA antagonists. 2. trans 2-carboxy-4-substituted tetrahydroquinolines.(1993)85 cited
- → Development of an intact cell reporter gene β-lactamase assay for G protein-coupled receptors for high-throughput screening(2003)84 cited
- → Discovery of the Potent and Selective M1 PAM-AgonistN-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects(2016)83 cited